This Week in Nature

In Nature Biotechnology this week, a team led by Massachusetts Institute of Technology researchers report on the use of a gene-editing approach called CRISPR to correct a disease mutation and phenotype in mice, furthering the therapeutic potential of the technology. In the study, the scientists were able to deliver into the animals the Cas9 nuclease, along with a snippet of RNA that directed the enzyme to a specific portion of DNA where it causes double-strand breaks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.